


HEALTH SERVICES 2023



Viridian Therapeutics Inc.\DE Rank 13 of 91





HEALTH SERVICES 2023



Viridian Therapeutics Inc.\DE Rank 13 of 91



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 353% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Other Revenues, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 196% points above the market average of 12%.

| Input Variable | Value in 1000 USD |
|---------------------------------------|----------------------|
| Assets, Current | 431,173 |
| Assets, Non-Current | 2,592 |
| Cost of Goods and Services Sold | 0 |
| Depreciation, Depletion, Amortization | 0 |
| General and Administrative Expense | 35,182 |
| Goodwill Impairment Loss | 0 |
| Intangible Assets | 0 |
| Labor Expense | 0 |
| Liabilities, Current | 33,349 |
| Long Term Liabilities | 1,172 |
| Operating Costs and Expenses | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | -233 |
| Other Expenses | 100,894 |
| Other Liabilities | 5,506 |
| Other Net Income | 4,430 |
| Other Revenues | 1,772 |
| Property Plant and Equipment | 1,326 |
| Research And Development Expense | 0 |
| Selling and Marketing Expense | 0 |

| | Value in |
|--------------------------|----------|
| Output Variable | |
| | 1000 USD |
| Assets | 435,091 |
| Liabilities | 40,027 |
| Expenses | 136,076 |
| Revenues | 1,772 |
| Stockholders Equity | 395,064 |
| Net Income | -129,874 |
| Comprehensive Net Income | -130,107 |
| Economic Capital Ratio | 208% |

